✦ LIBER ✦

Modelling cost-effectiveness in osteoporosis

✍ Scribed by John A. Kanis; Judith Adams; Fred Borgström; Cyrus Cooper; Bengt Jönsson; Danielle Preedy; Peter Selby; Juliet Compston

Book ID: 116320616
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 115 KB
Volume: 43
Category: Article
ISSN: 8756-3282
DOI: 10.1016/j.bone.2008.02.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness modelling in osteopor

Cost-effectiveness modelling in osteoporosis: alternatives to NICE

✍ Pam Brown 📂 Article 📅 2009 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 313 KB

PMS26 COST-EFFECTIVENESS MODELING IN OST

PMS26 COST-EFFECTIVENESS MODELING IN OSTEOPOROSIS: A SYSTEMATIC LITERATURE REVIEW AND OVERVIEW

✍ H.J. Smolen; J.A. Myers; L.J. Smolen 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Cost-effectiveness model of using zoledr

Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis

✍ Patrice Fardellone; Bernard Cortet; Erick Legrand; Xavier Bresse; Ségolène Bisot 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 232 KB

Gaussian Process Modeling in Conjunction

Gaussian Process Modeling in Conjunction with Individual Patient Simulation Modeling: A Case Study Describing the Calculation of Cost-Effectiveness Ratios for the Treatment of Established Osteoporosis

✍ Stevenson, M.D.; Oakley, J.; Chilcott, J.B. 📂 Article 📅 2004 🏛 SAGE Publications 🌐 English ⚖ 251 KB

POS7 COST-EFFECTIVENESS SIMULATION MODEL

POS7 COST-EFFECTIVENESS SIMULATION MODELING OF THE COMPLIANCE OF 5 MG ZOLEDRONIC ACID ONCE A YEAR VERSUS CURRENT TREATMENTS IN POST-MENOPAUSAL OSTEOPOROSIS

✍ P Fardellone; B Cortet; T Thomas; E Legrand; X Bresse; S Bisot-Locard; A Beresni 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

Cost-effectiveness research in osteoporo

Cost-effectiveness research in osteoporosis

✍ D. Coyle; A. Cranney; K.M. Lee; V. Welch; P. Tugwell 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

The clinical and economic burden of osteoporosis is high and has resulted in increasing interest in assessing the costs and benefits associated with strategies to reduce the incidence of fracture. In this article, we aim to summarize the major issues related to conducting economic evaluations of the